InvestorsHub Logo
Followers 30
Posts 2559
Boards Moderated 0
Alias Born 04/01/2009

Re: cantwate post# 485

Thursday, 01/17/2019 5:27:42 PM

Thursday, January 17, 2019 5:27:42 PM

Post# of 878
Not sure how the studies are progressing on BIV201, but their last 8k (see above) stated that they had reacquired certain rights for terlipressin.

item 2.01 Completion of Acquisition or Disposition of Assets

On December 24, 2018, BioVie Inc. (“BioVie”) completed the return of its partial ownership rights in a modified terlipressin program of PharmaIN Corporation (“ PharmaIN ”) and paid to PharmaIN the remaining $10,844 balance on a related debt for past services and other matters. BioVie had acquired the rights in that program, which is separate from and unrelated to the current BIV201 clinical development program, under a 2016 Commercialization Agreement with PharmaIN.



To me, that is not something I would do if I were staring at a brick wall. I think they are proceeding as to plan.

DISCLAIMER: All I say is just IMHO and does not constitute investment advice. My wife informs me frequently that I know nothing. I say you should trust no one on the internet.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent BIVI News